Hansa Biopharma announces the first commercial kidney transplant patient treated with Idefirix in Australia Hansa Biopharma AB, announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). AC Immune announces positive preliminary Phase 1 data […]
ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and […]
Sofinnova Partners announced Myricx Bio agrees to be acquired by Novartis Sofinnova Partners, a leading European life sciences venture capital firm, announced that its portfolio company Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestone payments. Sofinnova Partners seeded the […]
Hansa Biopharma announced the closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA Hansa Biopharma AB and SERB S.A. announced that the required regulatory approvals have been obtained and that the previously announced €115 million exclusive licensing transaction with SERB has closed. The company also announced that Maria Törnsén, […]
Here’s a novel thought: could the science that has enabled us to develop obesity drugs, be repurposed to help people put on weight? Now, the vast majority of us don’t, of course, need to put on weight. But some people do – notably many individuals with eating disorders such as anorexia nervosa. In a ‘Perspectives’ paper recently published in the New England Journal of Medicine, and an […]
